banner-01_about-us-copy

NEWS ROOM

Avantor Performance Materials has signed a collaboration agreement with Rubicon Research to combine Rubicon’s proprietary product technology to manufacture, market and develop next-generation products for the functional excipient market.

The research work that Rubicon has been working on for the last couple of years has culminated in this partnership with Avantor. We hope that this partnership will help us deliver the technology to various big pharma companies and will result into development of many differentiated innovative products for which Rubicon is already well known . This collaboration further adds to Rubicon’s reputation as a drug delivery and innovation based research company. It is also a momentous achievement for our Innovations and Licensing team which has laboured persistently and with perseverance to take this technology towards commercialization.

Rubicon, Avantor to develop new gastro-retentive excipient

PBR Staff Writer Published 17 October 2012

Avantor Performance Materials has signed a collaboration agreement with Rubicon Research to combine Rubicon’s proprietary product technology to manufacture, market and develop next-generation products for the functional excipient market.

The partnership will develop and market a new gastro-retentive excipient to deliver molecules having a window of absorption.

Avantor pharmaceuticals and the Americas executive vice president Paul Smaltz said the combination of Rubicon’s technology and the company’s market for functional excipients will result in outstanding products to help pharmaceutical customers in pursuit of patient dosage compliance, and safety.

“As we continue to be a trusted supplier of chemical compounds and materials, we’re also looking at similar arrangements to expand on our portfolio of drug delivery products and services, with the aim of providing even more value to our pharmaceutical customers in the future,” Smaltz added.

The companies will also collaborate to bring new products to the pharmaceutical excipient market, which includes optimized commercial manufacturing and production, regulatory registrations and approvals from the US FDA.

The two companies are expected to launch initial products resulting from the partnership in 2013.

Rubicon Research CEO Mrs. Pratibha Pilgaonkar said, “This material will provide solutions to the global pharmaceutical industry for molecules with challenging therapeutic requirements, either from the pipelines of innovator companies or for life cycle management opportunities for already marketed products.”

The two companies are expected to launch initial products resulting from the partnership in 2013 onwards.